Stanniocalcin-2: A Potential Predictor of Residual Breast Cancer After Neoadjuvant Chemotherapy

Compared to patients of pathological complete response (pCR), patients of residual lesion afterwards neoadjuvant chemotherapy (NAC) have worse prognosis and higher distant metastasis. Irrespective, there exists limited data on effective indicators and treatment methods for these patients. In our study, we evaluated the relationship between stanniocalcin-2 (STC2) marker and the prognosis of breast cancer patients of residual lesion after receiving NAC. The relationship between STC2 and patients’ prognosis was evaluated by transcriptome analysis. The impact of the level of STC2 on cell migration, invasion, and proliferation was evaluated at the cellular level. Immunohistochemistry was performed on 293 patients with residual disease after NAC to assess STC2 protein levels. The relationship between STC2 and survival rate was estimated using Cox regression model and Kaplan Meier analysis. The results demonstrated that high level of STC2 significantly inhibited migration, invasion, and proliferation of breast cancer cells. Compared to patients with low STC2, high STC2 were directly proportional to overall survival (OS) and disease-free survival (DFS) (OS: 86.96 vs. 84.62 months, P = 0.017 DFS: 77.33 vs. 66.95 months, P-value < 0.001). In conclusion, our research suggested that the of level STC2 may be a promising prognostic marker or therapeutic targe for breast cancer patients with residual lesion after NAC.

• Publication year

  2024

• Venue

  Journal of Biomedical Nanotechnology

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1166/jbn.2024.3881
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment

  2023cited by this paper
• Cancer survival prediction by learning comprehensive deep feature representation for multiple types of genetic data

  2023cited by this paper
• Radionanomedicine: Advanced Strategy for Precision Theranostics of Breast Cancer.

  2022cited by this paper
• Cancer statistics, 2022

  2022cited by this paper
• Mitochondria-Targeting-Based of Paclitaxel-Loaded Triphenylphosphine-Pluronic F127-Hyaluronic Acid Nanomicelles in Multi-Drug Resistant Hepatocellular Carcinoma

  2022cited by this paper
• Cauliflower bioactive compound sulforaphane inhibits breast cancer development by suppressing NF-κB /MMP-9 signaling pathway expression.

  2022cited by this paper
• Investigation of the Effects of the Endogenous Cannabinoid Anandamide on Luminal A Breast Cancer Cell Line MCF-7.

  2022cited by this paper
• Metastasis to the Pancreas From Ductal Carcinoma In Situ of Breast Cancer: A Case Report and Review of Literature.

  2022cited by this paper
• Pathologic complete response and survival after neoadjuvant chemotherapy in cT1-T2/N0 HER2+ breast cancer

  2022cited by this paper
• Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target

  2022cited by this paper
• Colorectal Cancer Lymph Node Detection and Anastomotic Safety of Using Carbon Nano-Tracer Following Minimally Invasive Radical Surgery

  2022cited by this paper
• Identifying Hub Genes Associated with Neoadjuvant Chemotherapy Resistance in Breast Cancer and Potential Drug Repurposing for the Development of Precision Medicine

  2022cited by this paper
• Circulating cell-free-DNA concentration is a good biomarker for diagnosis of colorectal cancer in Mexican patients.

  2022cited by this paper
• Long-term treatment patterns and survival in metastatic breast cancer by intrinsic subtypes – an observational cohort study in Sweden

  2022cited by this paper
• The novel prognostic risk factor STC2 can regulate the occurrence and progression of osteosarcoma via the glycolytic pathway.

  2021cited by this paper
• Stanniocalcin-2 promotes cell EMT and glycolysis via activating ITGB2/FAK/SOX6 signaling pathway in nasopharyngeal carcinoma

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021cited by this paper
• New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer

  2021cited by this paper
• The significance of Stanniocalcin 2 in malignancies and mechanisms

  2021cited by this paper
• Bioinformatics workflows for clinical applications in precision oncology.

  2021cited by this paper
• Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

  2020cited by this paper
• miR-381 Mediates the Development of Head and Neck Squamous Cell Carcinoma via Targeting STC2

  2020cited by this paper
• Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers.

  2019cited by this paper
• Overexpression of microRNA‐190 inhibits migration, invasion, epithelial‐mesenchymal transition, and angiogenesis through suppression of protein kinase B‐extracellular signal‐regulated kinase signaling pathway via binding to stanniocalicin 2 in breast cancer

  2019cited by this paper
• STC2 Is a Potential Prognostic Biomarker for Pancreatic Cancer and Promotes Migration and Invasion by Inducing Epithelial–Mesenchymal Transition

  2019cited by this paper
• Expression of Stanniocalcin 2 in Breast Cancer and Its Clinical Significance

  2019cited by this paper
• Upregulation of STC2 in colorectal cancer and its clinicopathological significance

  2019cited by this paper
• Clinical significance of high expression of stanniocalcin-2 in hepatocellular carcinoma

  2019cited by this paper
• Stanniocalcin Expression as a Predictor of Late Breast Cancer Recurrence

  2018cited by this paper
• Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer

  2018cited by this paper
• Assessment of pathological response to neoadjuvant chemotherapy in locally advanced breast cancer using the Miller-Payne system and TUNEL.

  2016cited by this paper
• STC2 promotes the epithelial-mesenchymal transition of colorectal cancer cells through AKT-ERK signaling pathways

  2016cited by this paper
• Stanniocalicin 2 Suppresses Breast Cancer Cell Migration and Invasion via the PKC/Claudin-1-Mediated Signaling

  2015cited by this paper
• Stanniocalcin-2 (STC2): A potential lung cancer biomarker promotes lung cancer metastasis and progression.

  2015cited by this paper
• Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis.

  2014cited by this paper
• Stanniocalcin 2 expression predicts poor prognosis of hepatocellular carcinoma

  2014cited by this paper
• Survival analyses correlate stanniocalcin 2 overexpression to poor prognosis of nasopharyngeal carcinomas

  2014cited by this paper
• Increased expression of stanniocalcin 2 is associated with tumor progression after radiotherapy in patients with cervical carcinoma.

  2014cited by this paper
• STC2 is upregulated in hepatocellular carcinoma and promotes cell proliferation and migration in vitro

  2012cited by this paper
• The role of brevican in glioma: promoting tumor cell motility in vitro and in vivo

  2012cited by this paper
• Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

  2012cited by this paper
• Tumor metastasis: molecular insights and evolving paradigms.

  2011cited by this paper
• Characterization of Phosphoproteins in Gastric Cancer Secretome

  2011cited by this paper
• Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells.

  2010cited by this paper
• Stanniocalcin-2 is a HIF-1 target gene that promotes cell proliferation in hypoxia.

  2010cited by this paper
• Clinicopathological significance of stanniocalcin 2 gene expression in colorectal cancer

  2009cited by this paper
• A worldwide approach to the TNM staging system: Collaborative efforts of the AJCC and UICC

  2009cited by this paper
• Stanniocalcin 2 overexpression in castration‐resistant prostate cancer and aggressive prostate cancer

  2009cited by this paper
• Stanniocalcin 2 expression is regulated by hormone signalling and negatively affects breast cancer cell viability in vitro.

  2008cited by this paper
• Identification of NTN4, TRA1, and STC2 as Prognostic Markers in Breast Cancer in a Screen for Signal Sequence Encoding Proteins

  2007cited by this paper
• Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach.

  2006cited by this paper
• Human stanniocalcin-2 exhibits potent growth-suppressive properties in transgenic mice independently of growth hormone and IGFs.

  2005cited by this paper
• Characterization of Stanniocalcin 2, a Novel Target of the Mammalian Unfolded Protein Response with Cytoprotective Properties

  2004cited by this paper
• Stanniocalcin 2 is an estrogen-responsive gene coexpressed with the estrogen receptor in human breast cancer.

  2002cited by this paper
• Molecular cloning of a second human stanniocalcin homologue (STC2).

  1998cited by this paper
• Combined chemotherapy and radiotherapy for locally advanced breast cancer.

  1980cited by this paper

• No citing papers are available for this paper.